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Background: Anthropometric measurements are useful in clinical practice since they are non-invasive and cheap.
Previous studies suggest that sagittal abdominal diameter (SAD) may be a better measure of visceral fat depots. The
aim of this study was to prospectively explore and compare how laboratory and anthropometric risk markers
predicted subclinical organ damage in 255 patients, with type 2 diabetes, after four years.
Methods: Baseline investigations were performed in 2006 and were repeated at follow-up in 2010. Carotid intima-
media thickness (IMT) was evaluated by ultrasonography and aortic pulse wave velocity (PWV) was measured with
applanation tonometry over the carotid and femoral arteries at baseline and at follow-up in a cohort of subjects
with type 2 diabetes aged 55–65 years old.
Results: There were significant correlations between apolipoprotein B (apoB) (r = 0.144, p = 0.03), C - reactive
protein (CRP) (r = 0.172, p = 0.009) at baseline and IMT measured at follow-up. After adjustment for sex, age,
treatment with statins and Hba1c, the associations remained statistically significant. HbA1c, total cholesterol or LDL-
cholesterol did not correlate to IMT at follow-up. Baseline body mass index (BMI) (r = 0.130, p = 0.049), waist
circumference (WC) (r = 0.147, p = 0.027) and sagittal Abdominal Diameter (SAD) (r = 0.184, p = 0.007) correlated to
PWV at follow-up. Challenged with sex, SBP and HbA1c, the association between SAD, not WC nor BMI, and PWV
remained statistically significant (p = 0.036). In a stepwise linear regression, entering both SAD and WC, the
association between SAD and PWV was stronger than the association between WC and PWV.
Conclusions: We conclude that apoB and CRP, but not LDL-cholesterol predicted subclinical atherosclerosis.
Furthermore, SAD was more independent in predicting arterial stiffness over time, compared with WC, in middle-
aged men and women with type 2 diabetes.
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Anthropometric measures are useful in clinical practice
since they are both non-invasive and cheap. Waist cir-
cumference (WC) is currently the most commonly used
measurement for abdominal obesity, and highly associ-
ated with the risk of developing CVD [1]. However, re-
cent studies suggest sagittal abdominal diameter (SAD)
to be a better measurement to assess an adverse meta-
bolic profile [2,3]. SAD has been shown to be strongly
related to cardiovascular risk [4,5] and mortality [6,7].
Cardiovascular disease (CVD) is the major cause of mor-
bidity and mortality in patients with type 2 diabetes.
Traditional risk factors such as high LDL cholesterol
and low HDL cholesterol, hypertension and smoking do
not fully explain the increased cardiovascular risk in pa-
tients with type 2 diabetes [8]. Therefore, it is of great
importance to identify better and non-invasive risk fac-
tor assessment tools to predict and ultimately to prevent
CVD in this group.
Furthermore abdominal obesity is associated with in-
creased levels of inflammatory markers [9]. Low- grade
inflammation is involved in the atherosclerotic process
and it has previously been shown that subjects with type
2 diabetes present with higher levels of inflammatory
markers compared to subjects without diabetes [10].
Systemic low grade inflammation can be measured as
circulating levels of the acute phase reactant C-Reactive
Protein (CRP) [11].
Intima media thickness (IMT) of the carotid arteries
measured by B-mode ultrasound is a well known, non-
invasive marker of subclinical atherosclerosis [12,13].
While Pulse wave velocity (PWV) measured by tonome-
try provides a non-invasive estimate of arterial stiffness
and is an independent predictive risk factor for all-cause
mortality and cardiovascular mortality [14-16].
The aim of this study was to prospectively explore
how laboratory and anthropometric risk factors pre-
dicted subclinical organ damage and, more specifically,
compare SAD and WC as risk markers for subclinical,
vascular organ damage, in a cohort of people with type 2
diabetes. A second aim was to explore the impact, over
time, from systemic low-grade inflammation and lipids
on arterial stiffness and atherosclerosis.
Methods
CARDIPP
We analyzed baseline data from the first 255 patients,
who participated in a community-based cohort study,
CARDIPP (Cardiovascular Risk factors in Patients with
Diabetes – a Prospective study in Primary care).
CARDIPP was launched in November 2005 and com-
pleted in 2008 with the aim to identify markers of cardio-
vascular disease to facilitate earlier and individually
adjusted intervention, in middle aged men and womenwith type 2 diabetes. CARDIPP comprises data on an ex-
tended annual follow up on patients with type 2 diabetes,
aged 55–66 years, consecutively recruited from 25 differ-
ent primary health care centers in the counties of
Östergötland and Jönköping, Sweden. All patients with
type 2 diabetes, aged 55–66 years, who attended an
annual follow-up at the health care centers, were consecu-
tively invited to participate in the study. Detailed informa-
tion about the structure and results from CARDIPP has
been described previously [17,18]. The centres were lo-
cated in different demographic areas and differed in size.
However, the model of treatment and care of type 2 dia-
betes was organized similarly and all primary care centres
adhered to the same national guidelines of diabetes care.
Anthropometric measurements
Nurses especially dedicated to treatment of diabetes at the
primary health care centers, measured height (to the
nearest cm) and weight (to the nearest 0.1 kg) with the pa-
tients wearing light indoor clothing. Waist circumference
(WC) was measured according to WHO’s recommenda-
tions with the patient standing, after a regular expiration,
to the nearest cm, midway between the lowest rib and the
iliac crest. SAD was recorded with the patient in the su-
pine position and with bent knees, with a standardized
sliding beam calliper at the highest point of the abdomen.
A standardized medical history was taken, including
data on diabetes duration and ongoing medication.
Laboratory tests
Blood specimens were drawn in the morning after a 10
hour over night fast. Routine tests such as HbA1c, plasma
glucose and serum lipids were analysed according to
routines at the primary health care centres. Levels of chol-
esterol, HDL and triglycerides was measured with enzym-
atic methodology and spectrophotometry, Selectra E,Vital
Scientefic, Netherlands/Triolab. LDL was calculated by
Friedewalds formula: LDL = cholesterol - HDL - 0.45 × fS/
P-triglycerides.
HbA1c was analysed according to the Swedish Mono-
S HPLC. In this study, all HbA1c values were converted
to DCCT standard values using the formula: HbA1c
DCCT = 0.923 × HbA1c (Mono-S) + 1.345 (R2 = 0.998)
[19] and data on HbA1c is also reported in IFCC units.
Blood samples were frozen for later analysis of CRP, apo-
lipoprotein B (apoB) and apolipoprotein A-I (apoA-I) at
the Centre for Laboratory medicine, Linköping Univer-
sity Hospital, Linköping, Sweden. Levels of apoB and
apoA-I were measured by immunoturbidimetric assays,
Advia 1800, DakoCytomation, Glostrup, Denmark. Coeffi-
cient of variation (CV) for apoB was 1.2% CV for apoA-I
was 1.8%. CRP was also measured by immunoturbidimetric
assays, Advia 1800, Siemens Diagnostic Medical Solutions,
Erlangen, Germany. The detection level was 0.12 mg/L and
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from the analyses according to current guidelines [20].
Physiological vascular examinations
The blood pressure measurements, carotid ultrasono-
graphic investigations, PWV and SAD were performed at
the Department of Physiology, Linköping University Hos-
pital, Linköping, Sweden and at the County Hospital
Ryhov, Jönköping, Sweden. Systolic blood pressure (SBP)
was measured with oscillometric technique (Dinamap
PRO 200 Monitor, Critikon, Tampa, FL, USA) on the same
occasion as the clinic physiological investigations. After at
least 10 minutes rest in supine position, using an appro-
priately sized cuff, the BP was recorded in both arms. The
mean value of two measurements in the arm with the
highest systolic BP was used in further analyses in the
study. IMT of the carotid arteries were evaluated using a
B-mode ultrasound. A digital ultrasound system (ATL
HDI 5000, Bothell, WA, USA) equipped with a broadband
linear transducer (L12-5) was used for scanning the ca-
rotid artery in longitudinal section. ECG leads were
connected. For lumen diameter (LD) and IMT determin-
ation, during diastole, three consecutive frozen images
with special focus on lumen-intima echo and media-
adventitia echo of the far arterial wall were saved for later
analysis. The digital B-mode images were subsequently
transferred to a PC, where software for off-line measure-
ment of LD and IMT is installed (Artery Measurement
System II, Image and Data Analysis, Gothenburg,
Sweden). Calibration and subsequent measurement was
performed by manually tracing a cursor along the leading
edge of the intima-lumen echo of the near wall, leading
edge of the lumen- intima echo and media-adventitia echo
of the far wall. A 10 mm long section of the common
carotid artery in the proximity of the carotid bulb was se-
lected to obtain mean LD and far wall IMT. During ana-
lysis, the measurement window was hidden for the reader
and values were saved in a text file. Mean values of IMT
and carotid LD from both the right and the left sides were
used in all analyses. Aortic PWV was measured with
applanation tonometry (SphygmoCorW system, model
MM3, AtCor Medical, Sydney, Australia) over the carotid
and femoral arteries. The aortic pulse wave transit times
were measured by electrocardiogram-guided readings of
the femoral arterial pulse waves, using the carotid arterial
pulse wave as the reference site. The surface distances
were estimated from the suprasternal notch to the carotid
and femoral measurement sites, respectively. PWV was
calculated by dividing the surface distance with the pulse
wave transit time yielding m × s-1.
CARDIPP-Revisited
The CARDIPP-R comprises a re-investigation of the
cohort four years after the completion of the baselineexamination. In CARDIPP-R, all participants from the
baseline study were invited to the re-investigation that
was conducted at the Department of Physiology,
Linköping University Hospital and at County Hospital
Ryhov, Jönköping, Sweden. This study population com-
prises subjects with type 2 diabetes who were subjected
to the baseline examination in 2006 and underwent the
subsequent re-investigation in 2010.
The CARDIPP-R study protocol for the blood pressure
measurements, the carotid ultrasonographic investiga-
tions and tonometry for measurements of the carotid,
femoral and radial pulse pressure wave form and pulse
wave velocity followed identical manual as in the base-
line investigation. The routine laboratory tests were
performed at the different health-care centers as de-
scribed in the baseline protocol. In the follow-up investi-
gation, CRP was not measured with an identical method
as at baseline, thus our results regarding CRP values are
confined to baseline data only.
Statistics
IBM SPSS statistics 19 (IBM corporation, Somers, NY,
USA) was used for statistical analyses. CRP, was log
transformed due to skewed distribution. Pearson correl-
ation coefficients were calculated between the different
measurements, using bivariate correlation analysis. Stat-
istical significance was assumed when p < 0.05. In mul-
tiple linear regression analyses with IMT or PWV, as
dependent variables, the increase of one unit for each of
the variables explored, confered a change in IMT or
PWV respectively expressed as the regression coefficient
(beta) with 95 percent confidence intervals (CI). In step-
wise linear regression criteria for entry were p < 0.05 and
for removal p > 0.1.
Ethics
All participants gave written informed consent prior to
participating in the study. The study, which complied
with the declaration of Helsinki, was approved by the
Regional Ethical Review Board in Linköping, Sweden.
Results
At the baseline investigation 64, (25%) patients were
treated with diet and exercise only and the remaining
patients were treated with oral glucose-lowering agents,
n = 97, (38%), or insulin alone or in combination with
oral glucose-lowering agents, n = 94, (37%). 121 (48%)
patients were treated with statins and 164 (64%) pa-
tients reported treatment with antihypertensive agents.
At the baseline investigation 2 subjects (0.8%) reported
previous stroke and 23 (9%) subjects reported previous
myocardial infarction. Table 1 displays the characteris-
tics of the 255 subjects according to gender, at baseline
investigation 2006 and at follow-up 2010. Figure 1
Table 1 Characteristics at baseline investigation (2006) and follow-up four years later (2010), in 172 men and 83
women with type 2 diabetes
Baseline Follow-up
Characteristics
All Men Women All Men Women Δ All
mean (sd) mean (sd) mean (sd) mean (sd) mean (sd) mean (sd) mean (sd)
Age (years) 61 (2.8) 61 (2.9) 61 (2.6) 65 (2.9) 65 (2.9) 65 (2.7) 4
BMI (kg/m2) 29.6 (5.0) 29.3 (4.7) 30.2 (5.5) 29.8 (5.1) 29.4 (5.0) 30.6 (5.3) 0.2 (2.2)
Sagittal Abdominal Diameter (cm) 25.2 (4.1) 25.4 (4.1) 24.8 (4.0) 25.9 (4.5) 26.0 (4.6) 25.8 (4.3) 0.6 (2.9)*
Waist circumference (cm) 102.4 (12.5) 103.2 (12.3) 100.5 (13.3) 105.6 (12.4) 106.1 (12.4) 104.5 (12.6) 3.3 (6.6)*
Systolic Bloodpressure (mmHg) 131 (17) 132 (16) 130 (17) 131 (16) 131 (15) 132 (21) 0.3 (17)
Diastolic Bloodpressure (mmHg) 75 (9) 77 (8) 70 (8) 73 (9) 75 (21) 69 (9) −1.7 (8.5)*
HbA1c (% units) 7.0 (1.0) 7.0 (1.0) 7.0 (1.0) 7.2 (0.9) 7.2 (0.9) 7.3 (0.8) 0.23 (1.0)*
HbA1c (mmol/mol) 53.2 (11.6) 52.9 (11.6) 53.7 (11.8) 56.1 (9.8) 55.5 (10.2) 57.2 (8.9) 2.6 (10.9)*
Total cholesterol (mmol/L) 4.7 (1.0) 4.6 (0.9) 5.0 (1.0) 4.4 (1.0) 4.3 (1.0) 4.4 (0.9) −0.4 (1.1)*
LDL cholesterol (mmol/L 2.6 (0.8) 2.6 (0.6) 2.3 (0.9) 2.4 (0.8) 2.4 (0.9) 2.3 (0.7) −0.3 (0.9)*
HDL cholesterol (mmol/L) 1.4 (0.3) 1.3 (0.3) 1.5 (0.3) 1.2 (0.3) 1.2 (0.3) 1.3 (0.4) −0.1 (0.2)*
Non HDL cholesterol (mmol/L) 3.4 (1.0) 3.3 (0.9) 3.6 (1.1) 3.1 (0.9) 3.1 (0.9) 3.1 (0.9) −0.3 (1.1)*
ApoB/ApoA-I 0.73 (0.17) 0.73 (0.16) 0.71 (0.19) 0.66 (0.20) 0.68 (0.20) 0.61 (0.18) −0.08 (0.18)*
ApoB 0.95 (0.19) 0.94 (0.18) 0.97 (0.20) 0.88 (0.21) 0.89 (0.21) 0.86 (0.21) −0.08 (0.21)*
Serum Triglycerides (mmol/L)** 1.5 (6.5) 1.4 (6.4) 1.5 (4.4) 1.4 (6.0) 1.4 (6.0) 1.5 (3.4) −0.09 (7.5)
Pulse wave velocity (m/s) 10.2 (2.2) 10.3 (2.2) 10.0 (2.2) 11.0 (2.4) 11.1 (2.4) 11.0 (2.5) 0.84 (1.9)*
Intima-Media Thickness (mm) 0.70 (0.17) 0.70 (0.18) 0.67 (0.14) 0.78 (0.20) 0.79 (0.23) 0.77 (0.15) 0.09 (0.2)*
Treatment with statins n (%) 121 (47.5%) 81 (47%) 40 (48.2%) 175 (69%) 111 (61%) 64 (78%) 54 (21%)*
Smoking n (%) 41 (16%) 24 (14%) 17 (20.5%) 35 (14%) 19 (11%) 16 (19.5%) −6 (−2%)*
* Difference at p < 0.01 level ** Data on variables with skewed distribution are given with median and interquartile range.
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line variables and PWV and IMT measured at follow-up
four years later. There were significant correlations be-
tween IMT and; apoB, CRP and systolic blood pressure
(SBP) and there were significant correlations between
PWV and; diabetes duration, SBP, BMI, WC and SAD.
In Table 2, SBP, apoB and CRP that came out as
correlated to IMT in Figure 1, remained statistically sig-
nificant associated to IMT when further challenged in
multiple linear regression analyses with IMT as
dependent variable adjusted for baseline age, sex, treat-
ment with statins, HbA1c. In Table 3, the associations
between SBP, BMI, WC and SAD to PWV, were further
challenged with sex, SBP and HbA1c. In these analyses
the association between SAD, but not WC or BMI, and
PWV remained statistically significant. In a stepwise lin-
ear regression, not in Table, entering both SAD and
WC, the association between SAD at baseline and PWV
at follow-up, was stronger than the association between
WC and PWV. In Figure 2 the relation between the
change (Δ) in WC and SAD is shown in a simple
scatterplot. Δ WC shows greater variability compared to Δ
SAD.Discussion
To the best of our knowledge this is the first prospective
study comparing SAD and WC, exploring the associa-
tions between abdominal obesity and arterial stiffness
measured as PWV, in men and women with type 2 dia-
betes. We report that SAD was a more independent pre-
dictor for increased arterial stiffness over time compared
with WC. Previous studies have shown that SAD is a
predictor of insulin resistance and levels of CRP in im-
migrant women from the middle-east [2] as well as in
obese men [3] and that SAD is closely related to visceral
adiposity [21,22]. In a recent, prospective study of a
Finnish population SAD was more predictive of incident
diabetes compared to WC [23]. Visceral fat is a potent
source for expression of proinflammatory, atherogenic
cytokines and is closely related to levels of inflammatory
markers [24]. Recent studies have also shown that redu-
cing the visceral fat improves endothelial dysfunction,
which is an early predictor for cardiovascular disease
[25]. Persons with type 2 diabetes have an increased risk
of all-cause mortality compared to a population without
diabetes [26] and cardiovascular disease is the major
cause of morbidity and mortality in these subjects.
Figure 1 Correlation between baseline characteristics 2006 and IMT and PWV 2010. LDL; low-density lipoprotein, nonHDL; non high-
density lipoprotein, apoB; apolipoprotein B, CRP; c-reactive protein, SBP; systolic blood pressure, BMI; body mass index; SAD; sagittal abdominal
diameter, WC; waist circumference. * Correlation significant at p < 0.05, ** correlation significant at p < 0.01.
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to consider in clinical practice. SAD has a high reliability
in both lean and obese subjects [27]. WC can be mea-
sured in various ways and there is no consensus about
which is the best measurement protocol [28]. In this
study we have chosen the method of measuring WC
recommended by WHO, where WC is measured mid-
way between the last rib and the iliac crest and not atTable 2 Associations between IMT and baseline levels of
CRP, apoB, and systolic BP as independent variables one
by one in different settings
IMT
Variable (Unit) Beta coefficient 95% CI P
CRP (mg L-1) 0.069 (0.013-0.125) 0.016
apoB (g L-1) 0.173 (0.015-0.331) 0.032
Systolic BP (mmHg) 0.002 (0.000-0.004) 0.026
Multiple linear regression analyses of IMT measured 2010 as dependent
variable adjusted for age, sex, treatment with statins, HbA1c measured at
baseline and PWV. The increase of one-unit for each of the variables confers a
change in IMT mm, expressed as the regression coefficient (Beta) with 95
percent CI.maximum WC, compared to SAD which is measured at
maximum abdominal height. This might partly explain
our finding that SAD was more robustly associated to
the change in arterial stiffness. SAD is a clinically feas-
ible measurement with high reproducibility, which gives
a good approximation of the atherogenic visceral fat. WC
can be measured in variable ways, at the maximum waist
or in the midline between the lower rib and iliac crest.Table 3 Associations between PWV and SBP, BMI, SAD
and WC as independent variables one by one in different
settings
PWV
Variable (Unit) Beta coefficient 95% CI p
SBP* (mmHg) 0.034 (0.015-0.053) <0.001
BMI (kg m2) 0.046 (−0.022-0.114) 0.181
SAD (cm) 0.092 (0.006-0.179) 0.036
WC (cm) 0.020 (−0.007-0.048) 0.143
Multiple linear regression analyses of PWV measured 2010, as dependent
variable adjusted for, sex, HbA1c and systolic blood pressure. The increase of
one-unit for each of the variables confers a change in PWV m s-1, expressed as
the regression coefficient (Beta) with 95 percent CI. * not adjusted for SBP.
Figure 2 Relation between changes in SAD (x-axis) and WC (y-axis) after 4 years from the baseline investigation both measured in cm.
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the subcutaneous fat is added to the visceral fat when
measuring waist and it could explain some of the differ-
ences compared to SAD. When measuring SAD the
patient is in the supine position which allows the subcuta-
neous fat to redistribute along the sides of the abdomen,
hence the height of the abdomen is more likely to provide
information on the amount of visceral fat.
Traditional risk factors such as high LDL cholesterol
and low HDL cholesterol, hypertension and smoking do
not fully explain the increased cardiovascular risk in pa-
tients with type 2 diabetes [8]. Therefore, it is of great
importance to identify and evaluate risk factor assess-
ment tools to predict and ultimately to prevent CVD.
ApoB is found in chylomicrons, VLDL, IDL and LDL
particles. Since each of these particles contains one sin-
gle apoB, measurement of apoB represents the total bur-
den of the lipoproteins considered most atherogenic.
Hence a consensus document from the American Dia-
betes association and the American College of Cardiology
Foundation for lipoprotein management in patients with
cardiometabolic risk, has suggested treatment goals for
apoB [29]. In recent large Asian studies, apoB was a
strong predictor of the metabolic syndrome [30] and
was proven to be reliably estimated by routine lipid
biochemistry [31]. In this numerically quite small obser-
vational prospective study we were able to confirm
previous findings that apoB is superior to conventional
lipids in predicting atherosclerotic related vasculardamage [32]. Furthermore, in this study baseline levels
of CRP predicted the development of subclinical athero-
sclerosis which may not come as a surprise since CRP is
a well known predictor of CVD and also of type 2
diabetes [33].
The major limitation of this prospective study is the
relatively small number of study subjects, which pre-
cludes subgroup analyses. Another limitation is that in-
sulin resistance, which is an independent predictor for
atherosclerosis and arterial stiffness [34], was not mea-
sured. Furthermore, the study-participants had multiple
risk factors for cardiovascular disease, such as hyperten-
sion and dyslipidemia, and hence we cannot specify
exact mechanistic progressive interactions of changes in
the different mediators of vascular disease. In particular
since these risk factors are affected by the medications
for these conditions.
Thus, there is still a need for further prospective stud-
ies on larger cohorts comparing the clinical utility of the
anthropometric measurements.
Conclusions
In summary, we conclude that SAD, if confirmed in fu-
ture, larger studies, may be used as a more independent
risk-assessment tool compared with WC in clinical prac-
tice, to identify persons with type 2 diabetes at high car-
diovascular risk. Furthermore the superiority of apoB over
LDL-cholesterol as predictor of subclinical atherosclerosis,
is in line with previous observational studies [35,36].
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